Uploaded December 2023 | Updated September 2026, 2 weeks ago
EB Research Partnership's CEO, Michael Hund, was a keynote speaker at the Chan Zuckerberg Initiative's 2023 Science in Society Annual Meeting: Advancing Patient-Driven Research In Rare Disease.
In this keynote to open the Patients Driving Breakthroughs and Progress in Rare Disease Research, Treatments, and Cures session, Michael highlights the organization's work to advance research in Epidermolysis Bullosa, leading to progress against the disease, including the recent FDA approval of Vyjuvek, the first-ever FDA approved treatment for EB.
EB Research Partnership's CEO, Michael Hund, was a keynote speaker at the Chan Zuckerberg Initiative's 2023 Science in Society Annual Meeting: Advancing Patient-Driven Research In Rare Disease.
In this keynote to open the Patients Driving Breakthroughs and Progress in Rare Disease Research, Treatments, and Cures session, Michael highlights the organization's work to advance research in Epidermolysis Bullosa, leading to progress against the disease, including the recent FDA approval of Vyjuvek, the first-ever FDA approved treatment for EB.
